Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

In this edition of Daily Dose, Dr. Lacy Anderson answers a viewer's question about what discounts are available for weight ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Plus, salon owners are seeing a massive drawdown in clients coming in for their regular scheduled appointments, citing ...

Also called undetected strokes, silent strokes are more common among older individuals, according to the American Health Association.

The triumph of Ozempic, Wegovy, and related drugs, including Lilly’s Zepbound, has set off a push toward the next frontier: a ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...

Medicaid plans often put up barriers around newer classes of diabetes medications that offer cardioprotection, according to a ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

More specifically, a 2024 study published in JAMA Network Open found a 45 percent higher risk of suicidal thoughts in people ...